Scholarlink

Background <p> Research studies have demonstrated that cardiotoxicity due to cancer treatments may be more prevalent in Black and other racial minority breast cancer (BC) patients. Our study examined racial disparities in receipt of BC treatments, with a focus on therapies associated with cardiotoxicity.</p> Methods <p> The study population included 12,350 female BC patients who were diagnosed with early-stage BC between January 1, 2011, and January 18, 2023, from an electronic health record-derived database. Odds ratios (ORs) and 95% confidence intervals (CI) were estimated using multivariable logistic regressions for the associations between race (Asian, Black/African American (AA), Other, White) and receipt of radiation and chemotherapy. A sensitivity analysis was conducted among 4,318 women who received chemotherapy to assess racial disparities in anthracycline use (chemotherapeutic agents known to be associated with cardiotoxicity).</p> Results <p> While most women received radiation (61.9%), only 35% received chemotherapy in the early-stage setting (of which 41.5% were anthracycline-based regimens). Black/AA women were more likely prescribed anthracycline-based chemotherapy than not (50.4%) compared to all other racial groups (White: 39.2%, Asian: 38.3%, Other: 44.7%). No significant associations were observed between race and radiation. We identified a racial disparity among other race women, who had a 21% (95% CI: 1.05, 1.40) higher odds of receiving chemotherapy than White women. Among women who received chemotherapy, no racial disparities were observed for receiving anthracyclines after adjusting for sociodemographic and tumor characteristics.</p> Conclusions <p> Our findings provide detailed real-world evidence on treatments among diverse BC patients. Future research should elucidate if treatment inequities drive cardiotoxic disparities.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Real-World Evaluation of Racial Disparities in the Receipt of Cancer Treatments and Anthracycline-Based Chemotherapies in Early-Stage Breast Cancer Patients

  • 期刊论文

  • 发表日期：

    2026年1月16日

查看全文
  • Katherine L. Ho,
  • Mu Jin,
  • Kala Visvanathan,
  • Avonne E. Connor

摘要

Background

Research studies have demonstrated that cardiotoxicity due to cancer treatments may be more prevalent in Black and other racial minority breast cancer (BC) patients. Our study examined racial disparities in receipt of BC treatments, with a focus on therapies associated with cardiotoxicity.

Methods

The study population included 12,350 female BC patients who were diagnosed with early-stage BC between January 1, 2011, and January 18, 2023, from an electronic health record-derived database. Odds ratios (ORs) and 95% confidence intervals (CI) were estimated using multivariable logistic regressions for the associations between race (Asian, Black/African American (AA), Other, White) and receipt of radiation and chemotherapy. A sensitivity analysis was conducted among 4,318 women who received chemotherapy to assess racial disparities in anthracycline use (chemotherapeutic agents known to be associated with cardiotoxicity).

Results

While most women received radiation (61.9%), only 35% received chemotherapy in the early-stage setting (of which 41.5% were anthracycline-based regimens). Black/AA women were more likely prescribed anthracycline-based chemotherapy than not (50.4%) compared to all other racial groups (White: 39.2%, Asian: 38.3%, Other: 44.7%). No significant associations were observed between race and radiation. We identified a racial disparity among other race women, who had a 21% (95% CI: 1.05, 1.40) higher odds of receiving chemotherapy than White women. Among women who received chemotherapy, no racial disparities were observed for receiving anthracyclines after adjusting for sociodemographic and tumor characteristics.

Conclusions

Our findings provide detailed real-world evidence on treatments among diverse BC patients. Future research should elucidate if treatment inequities drive cardiotoxic disparities.